Loading...
Market
Will Bavarian Nordic's stock price increase by 10% or more within 1 week of EU approval announcement?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from Nasdaq Copenhagen
Story
Bavarian Nordic Seeks EU Approval for Adolescent Mpox Vaccine
Aug 16, 2024, 07:30 AM
Danish biotech company Bavarian Nordic has submitted data to the European Union's drug regulator seeking approval to extend the use of its mpox vaccine to adolescents. Bavarian Nordic is currently the only company with a vaccine approved for mpox in both the United States and Europe. The company aims to expand the vaccine's usage to a younger demographic, highlighting its ongoing efforts to enhance public health measures against mpox.
View original story
Similar markets
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Increases by less than 5% • 25%
Decreases or remains the same • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
